探究心源性肝硬化（CC）患者血清Syndecan-1水平与心功能及肝硬化严重程度的相关性。

回顾性选取2022年1月至2024年10月西安医学院第三附属医院收治的139例慢性充血性心力衰竭患者作为研究对象，根据是否合并肝硬化将患者分为CC组42例和非CC组97例。收集患者基线资料，采用酶联免疫吸附试验检测血清Syndecan-1水平，采用Pearson/Spearman系数分析CC患者血清Syndecan-1水平与超声心动图参数指标[左心室射血分数（LVEF）、左心室短轴缩短分数（LVFS）、二尖瓣血流频谱E峰/A峰（E/A）]、心功能指标[心肌肌钙蛋白I（cTnI）、N末端B型利钠肽前体（NT-pro BNP）、肌酸激酶同工酶（CK-MB）]及肝功能[终末期肝病模型（MELD）评分、Child-Pugh评分]的相关性。

两组患者在血氨、总胆红素、直接胆红素、天冬氨酸转氨酶、丙氨酸转氨酶、超声心动图参数指标（LVEF、LVFS、E/A）、心功能指标（cTnI、NT-pro BNP、CK-MB）均有显著差异（均P<0.05）。血清Syndecan-1水平与LVEF、LVFS、E/A呈显著负相关（r=－0.692、－0.580、－0.695，均P<0.001）；血清Syndecan-1水平与cTnI、NT-pro BNP、CK-MB呈显著正相关（r=0.458、0.349、0.473，均P<0.001）；血清Syndecan-1水平与MELD、Child-Pugh评分呈显著正相关（r=0.457、0.693，均P<0.001）。

CC患者血清Syndecan-1水平显著升高，其水平变化与心功能及肝硬化严重程度密切相关，临床诊疗中需关注血清Syndecan-1水平变化。

To investigate the correlation between serum Syndecan-1 level and cardiac function and severity of cirrhosis in patients with cardiogenic cirrhosis (CC).

A total of 139 patients with chronic congestive heart failure admitted to the Third Affiliated Hospital of Xi'an Medical University from January 2022 to October 2024 were retrospectively selected as the research objects. The patients were divided into CC group (n=42) and non-CC group (n=97) according to whether they were complicated with liver cirrhosis. Baseline data of patients were collected, and serum Syndecan-1 levels were detected by enzyme-linked immunosorbent assay (ELISA). Pearson/Spearman coefficient was used to analyze the correlation between serum Syndecan-1 level and echocardiographic parameters [left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), mitral early diastolic inflow velocity/mitral late diastolic inflow velocity (E/A)] and cardiac function indicators [cardiac troponin I (cTnI), N-terminal pro-B-type natriuretic peptide (NT-pro BNP), creatine kinase isoenzyme (CK-MB)] and liver function [model for end-stage liver disease (MELD) score, Child-Pugh score] in CC patients.

There were significant differences between the two groups of patients in terms of blood ammonia, total bilirubin (TBIL), direct bilirubin (DBIL), aspartate aminotransferase (AST), alanine aminotransferase (ALT), echocardiogram parameters (LVEF, LVFS, E/A), cardiac function indicators (cTnI, NT-pro BNP, CK-MB) (all P<0.05). Serum Syndecan-1 level was negatively correlated with LVEF, LVFS and E/A (r=-0.692, r=-0.580, r=-0.695, all P<0.001). Serum Syndecan-1 levels was positively correlated with cTnI, NT-pro BNP and CK-MB (r=0.458, r=0.349, r=0.473, all P<0.001). Serum Syndecan-1 level was positively correlated with MELD and Child-Pugh scores (r=0.457, r=0.693, all P<0.001).

Serum Syndecan-1 level is significantly increased in patients with CC, and its change is closely related to cardiac function and the severity of cirrhosis. In clinical diagnosis and treatment, it is necessary to pay attention to the changes in serum Syndecan-1 levels.